CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...
The global clinical trial technology market is projected to reach USD 22.7 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.3%. Within this, AI-enabled patient recruitment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback